Is FARN or HZD more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% Horizon Discovery Group plc (HZD.L) N/A N/A N/A

Do analysts recommend PRTC or FARN?

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 326.89%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts clearly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, FARN or VRP?

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A Verona Pharma plc (VRP.L) N/A N/A N/A -£32.70 N/A

Is FARN or VRP more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% Verona Pharma plc (VRP.L) N/A N/A N/A

Do analysts recommend FARN or BTG?

BTG has a consensus target price of GBX 160, suggesting a potential upside of 50.02%. Given BTG's stronger consensus rating and higher probable upside, analysts clearly believe BTG is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is FARN or BTG more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% BTG N/A N/A N/A

Faron Pharmaceuticals Oy (FARN) Competitors

GBX 43.60 +1.30 (+3.07%)

As of 03:34 AM Eastern

Compare

FARN vs. HZD, PRTC, VRP, ARIX, and BTG

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? MarketBeat compares Faron Pharmaceuticals Oy with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Faron Pharmaceuticals Oy include Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and BTG (BTG). These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Faron Pharmaceuticals Oy (LON:FARN) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 1.43 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
Horizon Discovery Group plc (HZD.L)	Neutral

2.5% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Summary

Faron Pharmaceuticals Oy beats Horizon Discovery Group plc (HZD.L) on 5 of the 8 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

PureTech Health (LON:PRTC) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 326.89%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts clearly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Faron Pharmaceuticals Oy has lower revenue, but higher earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.17	-£91.86M	-£46.00	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

PureTech Health has a beta of 0.793, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, PureTech Health had 11 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 11 mentions for PureTech Health and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 1.43 beat PureTech Health's score of 1.35 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Positive
Faron Pharmaceuticals Oy	Positive

33.5% of PureTech Health shares are owned by institutional investors. Comparatively, 2.5% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

PureTech Health beats Faron Pharmaceuticals Oy on 8 of the 15 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Faron Pharmaceuticals Oy (LON:FARN) and Verona Pharma plc (VRP.L) (LON:VRP) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 1.43 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
Verona Pharma plc (VRP.L)	Neutral

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

Summary

Faron Pharmaceuticals Oy beats Verona Pharma plc (VRP.L) on 5 of the 7 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Faron Pharmaceuticals Oy (LON:FARN) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Arix Bioscience	105.64%	6.41%	2.18%

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 20.7% of Arix Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 1.43 beat Arix Bioscience's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
Arix Bioscience	Neutral

Faron Pharmaceuticals Oy has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 11 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to BTG?

Faron Pharmaceuticals Oy (LON:FARN) and BTG (LON:BTG) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

BTG has a consensus target price of GBX 160, suggesting a potential upside of 50.02%. Given BTG's stronger consensus rating and higher probable upside, analysts clearly believe BTG is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, BTG had 3 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 3 mentions for BTG and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 1.43 beat BTG's score of 0.34 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
BTG	Neutral

BTG has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
BTG	£159.40M	1.08	N/A	£6.00	17.78

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 19.2% of BTG shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 19.7% of BTG shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
BTG	N/A	N/A	N/A

Summary

BTG beats Faron Pharmaceuticals Oy on 10 of the 12 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FARN vs. The Competition

Export

Metric	Faron Pharmaceuticals Oy	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£88.46M	£3.54B	£6.86B	£2.83B
Dividend Yield	N/A	3.78%	2.59%	6.15%
P/E Ratio	-1.98	7.38	282.27	368.37
Price / Sales	N/A	1,190.93	563.88	83,518.43
Price / Cash	20.00	44.80	28.60	27.89
Price / Book	0.02	16.79	10.93	7.06
Net Income	-£60.23M	-£12.56M	£3.49B	£5.89B
7 Day Performance	3.81%	-1.79%	-0.61%	6.48%
1 Month Performance	4.68%	-8.42%	-3.75%	0.18%
1 Year Performance	-77.45%	48.61%	62.10%	64.41%

Faron Pharmaceuticals Oy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FARN Faron Pharmaceuticals Oy	N/A	GBX 43.60 +3.1%	N/A	-78.1%	£88.46M	N/A	N/A	34	Positive News Gap Down
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.4456 of 5 stars	GBX 123 -0.3%	GBX 508 +313.0%	-13.7%	£299.40M	£4.66M	N/A	300	News Coverage Positive News
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. HZD, PRTC, VRP, ARIX, and BTG

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. HZD, PRTC, VRP, ARIX, and BTG

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Does the media prefer FARN or HZD?

Do institutionals & insiders believe in FARN or HZD?

Is FARN or HZD more profitable?

Which has preferable valuation & earnings, FARN or HZD?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Is PRTC or FARN more profitable?

Do analysts recommend PRTC or FARN?

Which has stronger valuation and earnings, PRTC or FARN?

Which has more risk and volatility, PRTC or FARN?

Does the media refer more to PRTC or FARN?

Do institutionals & insiders hold more shares of PRTC or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Do insiders and institutionals believe in FARN or VRP?

Does the media favor FARN or VRP?

Which has better valuation and earnings, FARN or VRP?

Is FARN or VRP more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Is FARN or ARIX more profitable?

Do institutionals and insiders hold more shares of FARN or ARIX?

Which has stronger valuation and earnings, FARN or ARIX?

Does the media favor FARN or ARIX?

Which has more volatility and risk, FARN or ARIX?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Do analysts recommend FARN or BTG?

Does the media favor FARN or BTG?

Which has higher valuation and earnings, FARN or BTG?

Do insiders and institutionals hold more shares of FARN or BTG?

Is FARN or BTG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools